OppenheimerFunds Inc. lifted its holdings in shares of MEDNAX Inc (NYSE:MD) by 40.4% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 28,780 shares of the company’s stock after purchasing an additional 8,278 shares during the quarter. OppenheimerFunds Inc.’s holdings in MEDNAX were worth $1,538,000 as of its most recent SEC filing.
Other hedge funds have also bought and sold shares of the company. Fuller & Thaler Asset Management Inc. acquired a new stake in shares of MEDNAX during the third quarter worth $103,000. Meiji Yasuda Asset Management Co Ltd. boosted its holdings in shares of MEDNAX by 45.3% during the third quarter. Meiji Yasuda Asset Management Co Ltd. now owns 5,230 shares of the company’s stock worth $226,000 after purchasing an additional 1,630 shares during the last quarter. Delta Capital Management LLC acquired a new stake in shares of MEDNAX during the fourth quarter worth $227,000. Brown Advisory Inc. acquired a new stake in shares of MEDNAX during the fourth quarter worth $231,000. Finally, YHB Investment Advisors Inc. acquired a new stake in shares of MEDNAX during the fourth quarter worth $235,000. Institutional investors and hedge funds own 98.53% of the company’s stock.
MEDNAX Inc (NYSE MD) opened at $57.59 on Wednesday. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.18 and a quick ratio of 1.18. MEDNAX Inc has a 52-week low of $40.56 and a 52-week high of $71.00. The company has a market capitalization of $5,498.29, a PE ratio of 16.69, a price-to-earnings-growth ratio of 1.45 and a beta of 0.26.
MD has been the topic of a number of research analyst reports. Zacks Investment Research upgraded MEDNAX from a “hold” rating to a “buy” rating and set a $60.00 target price on the stock in a report on Tuesday, January 23rd. Stephens set a $62.00 target price on MEDNAX and gave the company a “buy” rating in a report on Thursday, February 8th. Jefferies Group set a $50.00 target price on MEDNAX and gave the company a “hold” rating in a report on Tuesday, February 6th. Mizuho set a $49.00 target price on MEDNAX and gave the company a “hold” rating in a report on Wednesday, January 24th. Finally, Stifel Nicolaus reiterated a “hold” rating and issued a $56.00 target price on shares of MEDNAX in a report on Wednesday, January 24th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $54.92.
MEDNAX Company Profile
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MEDNAX Inc (NYSE:MD).
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.